These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ; J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461 [TBL] [Abstract][Full Text] [Related]
3. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E; Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099 [TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology. Benenati J; Shlansky-Goldberg R; Meglin A; Seidl E; J Vasc Interv Radiol; 2001 Jul; 12(7):795-805. PubMed ID: 11435535 [No Abstract] [Full Text] [Related]
5. Facilitated percutaneous intervention following combination therapy with reteplase and abciximab for acute myocardial infarction. Weinstock BS J Invasive Cardiol; 2002 Feb; 14(2):100-4; quiz 104-5. PubMed ID: 11818648 [No Abstract] [Full Text] [Related]
6. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ; JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372 [TBL] [Abstract][Full Text] [Related]
7. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430 [TBL] [Abstract][Full Text] [Related]
8. Management of acute coronary syndromes. Schulman SP; Fessler HE Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971 [No Abstract] [Full Text] [Related]
10. Coupling drug and catheter therapy for myocardial infarction. Lincoff AM JAMA; 2004 Feb; 291(8):1000-2. PubMed ID: 14982917 [No Abstract] [Full Text] [Related]
11. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598 [TBL] [Abstract][Full Text] [Related]
12. Role of abciximab in the treatment of coronary artery disease. Gabriel HM; Oliveira EI Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260 [TBL] [Abstract][Full Text] [Related]
13. Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition. Bush HS J Emerg Med; 2003 Nov; 25(4):421-6. PubMed ID: 14654184 [TBL] [Abstract][Full Text] [Related]
14. [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct]. Nordt TK; Peter K; Bode C Herz; 2001 Apr; 26 Suppl 1():42-5. PubMed ID: 11349626 [TBL] [Abstract][Full Text] [Related]
15. Does thrombolytic therapy facilitate or foil primary PCI? Leopold JA N Engl J Med; 2008 May; 358(21):2277-9. PubMed ID: 18499572 [No Abstract] [Full Text] [Related]